Idec

• “Other biotech operations that are expanding in the area include Biogen Idec, which is relocating its headquarters to Kendall Square, and Pfizer Inc., which will move into a new research building being built by MIT, also in Kendall Square.”

  Boston.com Top Stories

• “The medicine competes with injected drugs including Biogen Idec 's Avonex and Teva Pharmaceutical Industries' Copaxone.”

  The Wall Street Journal: EU Regulator Reviews Novartis MS Pill

• “Biogen Idec Inc. said Tuesday its fourth-quarter earnings rose 25%, fueled by rising sales of multiple-sclerosis drugs, and that the company is making investments this year to fuel its research-and-development pipeline and prepare for product launches.”

  The Wall Street Journal: Biogen's Net Rises 25% as Company Invests in Pipeline

• “Separately, Biogen Idec Inc. said Tuesday its fourth-quarter earnings rose 25%, fueled by rising sales of multiple-sclerosis drugs.”

  The Wall Street Journal: Pfizer, Lilly Profits Fall as Drugs Lose Patents

• “Drug maker Biogen Idec Inc. is also building 495,000 square feet of new offices in Cambridge.”

  The Wall Street Journal: A Biotech Building Boom

• “The label of multiple sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan Corp., has been changed to include the updated incidence of a rare brain infection.”

  The Wall Street Journal: Biogen, Elan's Tysabri Label Updated

• “Mr. Martin said the restructured company will be able to focus more on its flagship multiple sclerosis treatment Tysabri which it manufactures and sells along with its U.S. joint venture partner Biogen Idec Inc.”

  The Wall Street Journal: Elan Sells EDT Unit to Alkermes

• “Biogen Idec Inc.'s oral drug for multiple sclerosis showed success in the first of two large clinical trials, moving the company closer to gaining a foothold in an important new market.”

  The Wall Street Journal: Biogen MS Pill Shows Promise in Clinical Trial

• “The Florida agency's resolution "was a catalyst" for Biogen Idec Inc. directors after it previously rejected declassification, recalls Naomi Aoki , a spokeswoman for the biotechnology business.”

  The Wall Street Journal: More Directors Face Yearly Votes

• “Biogen Idec Inc. is developing BG-12, and initial data earlier this year showed strong effectiveness that some believe will make the pill a market leader.”

  The Wall Street Journal: Mixed Results for Oral Multiple-Sclerosis Drug

Show 10 more examples...